Christopher Haqq - 30 Sep 2024 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Role: Title: Executive Vice President, Head of R&D and Chief Medical Officer
Signature: /s/ Christopher Haqq
Issuer symbol: ELTX
Transactions as of: 30 Sep 2024
Net transactions value: $0
Form type: 4
Filing time: 02 Oct 2024, 16:12:12 UTC
Previous filing: 05 Feb 2024
Next filing: 04 Feb 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELTX	Stock Option (Right to Buy)	Award	$0	+28,200		$0.000000	28,200	30 Sep 2024	Common Stock	28,200	$5.03	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Fifty percent (50%) of the stock options vest on September 30, 2025, the one-year anniversary of the grant date, with the remaining fifty percent (50%) of the stock options to vest on September 30, 2026, the two-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Remarks:

Title: Executive Vice President, Head of R&D and Chief Medical Officer